Across TCGA pan-cancer cohorts, ADM5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ADM5 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ADM5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADM5 expression acts as an unfavorable survival marker.

LIHC and BRCA are the cancer types where ADM5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.255	0.773	.012	9	view →
BRCA	DFS	Median	All	0.112	0.526	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ADM5 tumor-vs-normal RNA expression · all ADM5 data types